Tonix announces initiation of enrollment in MGH Phase 2 study of TNX-1900

Tonix Pharmaceuticals announced that the first participant was enrolled in the Phase 2 ‘POWER’ study of TNX-1900 for the treatment of pediatric obesity at the Massachusetts General Hospital, MGH. The aim of the study is to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to induce weight loss and improve indicators of cardiometabolic risk in adolescent patients with obesity. The 12-week double-blind, placebo-controlled trial has a target enrollment of 75 participants 12-18 years old with obesity. “More than two-thirds of the U.S. population suffers from obesity or is overweight1,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Available pharmacologic treatment options for weight loss in children are limited by safety/tolerability problems and failure to achieve sustained weight loss. It is essential to develop safe and effective therapeutic strategies for weight loss, particularly in adolescents, who are understudied while being at greatest risk for long-term comorbidities.”